Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: AstraZeneca AB
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A randomised, parallel group, single blind, multicentre, 9-month, phase IV study in a primary care setting, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guided by clinical symptoms and signs alone, in patients with heart failure and left ventricular systolic dysfunction
The primary objective is to evaluate if 9 months of heart failure treatment guided by clinical symptoms, signs and NT-proBNP values is more effective to reduce the combination of cardiovascular (CV) d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
An early phase study to evaluate the efficacy and safety of AZD1419 in patients with asthma
To assess the efficacy of inhaled AZD1419 in eosinophilic asthma patients after withdrawal of controller treatment of ICS + LABA, by evaluating Time to loss of asthma control
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) in Adult Patients with Acute Mania
The primary objective is to evaluate the effectiveness of lithium compared to placebo as an add on to quetiapine XR in the treatment of acute mania in subjects with bipolar I disorder, as assessed by ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and Sivastatin 40 mg and 80 mg in Combination with Ezetimibe 10 mg (fixed dose combination) in Patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20% (GRAVITY)
The primary objective of this study is to evaluate the LDL-C lowering efficacy of rosuvastatin 10 mg and 20 mg in combination with ezetimibe relative to that of simvastatin in a fixed dose combination...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy
The primary objective of this study is to demonstrate an improvement in PFS as assessed by RECIST criteria, for the combination of ZD6474 plus pemetrexed (Alimta®) compared with pemetrexed plus placeb...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A global study to compare the effects of fulvestrant and arimidex in a subset of patients with breast cancer Globalne badanie mające na celu porównanie działań fulwestrantu i arimideksu w podgrupie pacjentek z rakiem piersi
To demonstrate superior progression free survival for patients treated with fulvestrant 500mg versus patients treated with anastrozole 1mg Wykazanie dłuższego czasu przeżycia bez progresji choro...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer. Olaparib como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2
Efficacy of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS). evaluar el efecto del tratamiento adyuvante con olaparib sobre la supervivencia libre de enfermedad infiltr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease. Badanie oceniające, czy dapagliflozyna może zapobiec stopniowej utracie czynności nerek i wydłużyć przeżycie pacjentów z przewlekła chorobą nerek
To determine if dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of ≥50% sustained decline in estimated glomerular filtration rate (eGFR), reaching end ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
to investigate the safety of Entocort™ EC (budesonide) in a paediatric mild to moderate Crohn’s disease population for maintenance of clinical remission
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
Olaparib in gBRCA Mutated Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Olaparib en cáncer de páncreas metastásico con mutación de gBRCA cuya enfermedad no ha progresado con una quimioterapia de primera línea basada en el platino
To determine the efficacy of Olaparib maintenance monotherapy compared to placebo by progression free survival (PFS) Determinar la eficacia de la monoterapia de mantenimiento con olaparib en com...
Country
None
organs
None
Specialty
None
unknown
More information
1
2
3
4
5
6
7
8
9
10
Next